Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adherium Ltd. ( (AU:ADR) ) has issued an announcement.
Adherium Limited has issued a corrected quarterly cash flow report for the period ended 31 December 2025, amending several items in its previously lodged Appendix 4C. The revisions reclassify $3.545 million in proceeds from the exercise of options within the financing cash flow section, separately disclose a previously aggregated $0.200 million item from the prior quarter, and adjust reported financing facilities from an $8.388 million loan to a mix of $0.550 million in loan facilities and $0.451 million in convertible notes, with related sections updated accordingly; the company confirmed the corrections do not affect its reported quarter-end cash balance.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australia-based provider of integrated digital health solutions and a global leader in connected respiratory medical devices. Its FDA-cleared Hailie Smartinhaler platform enables clinicians, healthcare providers and patients to remotely monitor medication usage and adherence for respiratory disease management, supported by mobile and desktop apps, SDKs, APIs and a broad range of connected sensors aimed at improving visibility into medication use and supporting reimbursement for qualifying patient management.
Technical Sentiment Signal: Sell
Current Market Cap: A$18.55M
See more data about ADR stock on TipRanks’ Stock Analysis page.